SA
CRBP icon

Scarborough Advisors’s Corbus Pharmaceuticals CRBP Stock Holding History

Scarborough Advisors’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6
Closed -$56 – 253
2026
Q1 		$56 Hold
6
– – ﹤0.01% 744
2025
Q4 		$49 Hold
6
– – ﹤0.01% 452
2025
Q3 		$76 Hold
6
– – ﹤0.01% 457
2025
Q2 		$41 Buy
+6
New +$44 ﹤0.01% 456
2024
Q3 		– Sell
-6
Closed -$272 – 191
2024
Q2 		$272 Hold
6
– – ﹤0.01% 394
2024
Q1 		$235 Hold
6
– – ﹤0.01% 381
2023
Q4 		$36 Buy
+6
New +$32 ﹤0.01% 716

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Scarborough Advisors's CRBP Position: Q2 2026 in Review

Scarborough Advisors sold out of Corbus Pharmaceuticals (CRBP) in Q2 2026, closing a stake of 6 shares — an estimated $56 sold.

Scarborough Advisors first reported a position in CRBP in Q4 2023 and held it in 7 quarters. The position peaked at $272 in Q2 2024. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • Scarborough Advisors reported no remaining Corbus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Scarborough Advisors sold 6 Corbus Pharmaceuticals shares in Q2 2026, an estimated $56.
  • Scarborough Advisors first reported a position in Corbus Pharmaceuticals in Q4 2023 and held it in 7 quarters.
  • Scarborough Advisors's Corbus Pharmaceuticals position peaked at $272 in Q2 2024.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on Scarborough Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.